Data di Pubblicazione:
2019
Abstract:
Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.
Tipologia CRIS:
03B-Review in Rivista / Rassegna della Lett. in Riv. / Nota Critica
Elenco autori:
Calin G.A.; Pardini B.
Link alla scheda completa:
Pubblicato in: